These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 34999925)
1. Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents. Korsen M; Pfeuffer S; Rolfes L; Meuth SG; Hartung HP J Neurol; 2022 May; 269(5):2806-2818. PubMed ID: 34999925 [TBL] [Abstract][Full Text] [Related]
2. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Gonzalez-Lorenzo M; Ridley B; Minozzi S; Del Giovane C; Peryer G; Piggott T; Foschi M; Filippini G; Tramacere I; Baldin E; Nonino F Cochrane Database Syst Rev; 2024 Jan; 1(1):CD011381. PubMed ID: 38174776 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Roos I; Sharmin S; Malpas C; Ozakbas S; Lechner-Scott J; Hodgkinson S; Alroughani R; Eichau Madueño S; Boz C; van der Walt A; Butzkueven H; Buzzard K; Skibina O; Foschi M; Grand'Maison F; John N; Grammond P; Terzi M; Prévost J; Barnett M; Laureys G; Van Hijfte L; Luis Sanchez-Menoyo J; Blanco Y; Oh J; McCombe P; Ramo Tello C; Soysal A; Prat A; Duquette P; Yamout BI; Khoury S; van Pesch V; Macdonell R; José Sá M; Slee M; Kuhle J; Maimone D; Spitaleri D; Willekens B; Asmi AA; Tallantyre E; Robertson NP; Coles A; L Brown JW; Kalincik T Mult Scler; 2024 Aug; 30(9):1163-1175. PubMed ID: 39087208 [TBL] [Abstract][Full Text] [Related]
4. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. Śladowska K; Kawalec P; Holko P; Osiecka O Neurol Sci; 2022 Sep; 43(9):5479-5500. PubMed ID: 35713731 [TBL] [Abstract][Full Text] [Related]
5. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. Zhu C; Zhou Z; Roos I; Merlo D; Kalincik T; Ozakbas S; Skibina O; Kuhle J; Hodgkinson S; Boz C; Alroughani R; Lechner-Scott J; Barnett M; Izquierdo G; Prat A; Horakova D; Kubala Havrdova E; Macdonell R; Patti F; Khoury SJ; Slee M; Karabudak R; Onofrj M; Van Pesch V; Prevost J; Monif M; Jokubaitis V; van der Walt A; Butzkueven H; J Neurol Neurosurg Psychiatry; 2022 Dec; 93(12):1330-1337. PubMed ID: 36261289 [TBL] [Abstract][Full Text] [Related]
6. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis. Boz C; Ozakbas S; Terzi M; Karabudak R; Sevim S; Turkoglu R; Soysal A; Balcı BP; Efendi H; Turan ÖF; Yüceyar N; Yetkin MF; Karahan SZ; Demirkıran M; Guler S; Agan K; Kıylıoğlu N; Baba C; Tuncer A; Köseoğlu M Neurol Sci; 2023 Jun; 44(6):2121-2129. PubMed ID: 36689010 [TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Spelman T; Herring WL; Zhang Y; Tempest M; Pearson I; Freudensprung U; Acosta C; Dort T; Hyde R; Havrdova E; Horakova D; Trojano M; De Luca G; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Alroughani R; Pucci E; Granella F; Lechner-Scott J; Sola P; Ferraro D; Grand'Maison F; Terzi M; Rozsa C; Boz C; Hupperts R; Van Pesch V; Oreja-Guevara C; van der Walt A; Jokubaitis VG; Kalincik T; Butzkueven H; Pharmacoeconomics; 2022 Mar; 40(3):323-339. PubMed ID: 34921350 [TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom. Spelman T; Herring WL; Acosta C; Hyde R; Jokubaitis VG; Pucci E; Lugaresi A; Laureys G; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Ozakbas S; Alroughani R; Kalincik T; Duquette P; Girard M; Petersen T; Patti F; Csepany T; Granella F; Grand'Maison F; Ferraro D; Karabudak R; Jose Sa M; Trojano M; van Pesch V; Van Wijmeersch B; Cartechini E; McCombe P; Gerlach O; Spitaleri D; Rozsa C; Hodgkinson S; Bergamaschi R; Gouider R; Soysal A; Castillo-Triviño ; Prevost J; Garber J; de Gans K; Ampapa R; Simo M; Sanchez-Menoyo JL; Iuliano G; Sas A; van der Walt A; John N; Gray O; Hughes S; De Luca G; Onofrj M; Buzzard K; Skibina O; Terzi M; Slee M; Solaro C; Oreja-Guevara ; Ramo-Tello C; Fragoso Y; Shaygannejad V; Moore F; Rajda C; Aguera Morales E; Butzkueven H J Med Econ; 2024; 27(1):109-125. PubMed ID: 38085684 [TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study. Brownlee WJ; Haghikia A; Hayward B; Waser N; Kayaniyil S; Khan Z; Duncan J; Millar S; Harty GT Mult Scler Relat Disord; 2023 Aug; 76():104791. PubMed ID: 37343465 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis. Fakih AU; Sahraian MA; Paybast S; Naser Moghadasi A Mult Scler Relat Disord; 2023 Mar; 71():104564. PubMed ID: 36863084 [TBL] [Abstract][Full Text] [Related]
11. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Kalincik T; Brown JWL; Robertson N; Willis M; Scolding N; Rice CM; Wilkins A; Pearson O; Ziemssen T; Hutchinson M; McGuigan C; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Alroughani R; Pucci E; Sola P; Hupperts R; Lechner-Scott J; Terzi M; Van Pesch V; Rozsa C; Grand'Maison F; Boz C; Granella F; Slee M; Spitaleri D; Olascoaga J; Bergamaschi R; Verheul F; Vucic S; McCombe P; Hodgkinson S; Sanchez-Menoyo JL; Ampapa R; Simo M; Csepany T; Ramo C; Cristiano E; Barnett M; Butzkueven H; Coles A; Lancet Neurol; 2017 Apr; 16(4):271-281. PubMed ID: 28209331 [TBL] [Abstract][Full Text] [Related]
12. Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study. Bigaut K; Kremer L; Fabacher T; Ahle G; Goudot M; Fleury M; Gaultier C; Courtois S; Collongues N; de Seze J J Neurol; 2022 Jun; 269(6):3295-3300. PubMed ID: 34982200 [TBL] [Abstract][Full Text] [Related]
13. Prediction of multiple sclerosis outcomes when switching to ocrelizumab. Zhong M; van der Walt A; Stankovich J; Kalincik T; Buzzard K; Skibina O; Boz C; Hodgkinson S; Slee M; Lechner-Scott J; Macdonell R; Prevost J; Kuhle J; Laureys G; Van Hijfte L; Alroughani R; Kermode AG; Butler E; Barnett M; Eichau S; van Pesch V; Grammond P; McCombe P; Karabudak R; Duquette P; Girard M; Taylor B; Yeh W; Monif M; Gresle M; Butzkueven H; Jokubaitis VG Mult Scler; 2022 May; 28(6):958-969. PubMed ID: 34623947 [TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. Kalincik T; Sharmin S; Roos I; Freedman MS; Atkins H; Burman J; Massey J; Sutton I; Withers B; Macdonell R; Grigg A; Torkildsen Ø; Bo L; Lehmann AK; Havrdova EK; Krasulova E; Trnený M; Kozak T; van der Walt A; Butzkueven H; McCombe P; Skibina O; Lechner-Scott J; Willekens B; Cartechini E; Ozakbas S; Alroughani R; Kuhle J; Patti F; Duquette P; Lugaresi A; Khoury SJ; Slee M; Turkoglu R; Hodgkinson S; John N; Maimone D; Sa MJ; van Pesch V; Gerlach O; Laureys G; Van Hijfte L; Karabudak R; Spitaleri D; Csepany T; Gouider R; Castillo-Triviño T; Taylor B; Sharrack B; Snowden JA; ; ; Mrabet S; Garber J; Sanchez-Menoyo JL; Aguera-Morales E; Blanco Y; Al-Asmi A; Weinstock-Guttman B; Fragoso Y; de Gans K; Kermode A; JAMA Neurol; 2023 Jul; 80(7):702-713. PubMed ID: 37437240 [TBL] [Abstract][Full Text] [Related]
15. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858 [TBL] [Abstract][Full Text] [Related]
16. Reasons for switching to fingolimod in patients relapsing-remitting multiple sclerosis in France: the ESGILE study. Tourbah A; Papeix C; Tourniaire P; Rerat K; Meite M; Durand B; Lamy F; Chouette I; Mekies C; Mult Scler Relat Disord; 2020 Nov; 46():102433. PubMed ID: 32862037 [TBL] [Abstract][Full Text] [Related]